These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 23048018

  • 1. Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys.
    Cubillo A, Smith AB, Barrett N, Giampietro V, Brammer MJ, Simmons A, Rubia K.
    Cereb Cortex; 2014 Jan; 24(1):174-85. PubMed ID: 23048018
    [Abstract] [Full Text] [Related]

  • 2. Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory.
    Cubillo A, Smith AB, Barrett N, Giampietro V, Brammer M, Simmons A, Rubia K.
    Psychol Med; 2014 Feb; 44(3):633-46. PubMed ID: 23597077
    [Abstract] [Full Text] [Related]

  • 3. Neurofunctional effects of methylphenidate and atomoxetine in boys with attention-deficit/hyperactivity disorder during time discrimination.
    Smith A, Cubillo A, Barrett N, Giampietro V, Simmons A, Brammer M, Rubia K.
    Biol Psychiatry; 2013 Oct 15; 74(8):615-22. PubMed ID: 23731741
    [Abstract] [Full Text] [Related]

  • 4. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP, Fan J, Bédard AC, Clerkin SM, Ivanov I, Tang CY, Halperin JM, Newcorn JH.
    Arch Gen Psychiatry; 2012 Sep 15; 69(9):952-61. PubMed ID: 22945622
    [Abstract] [Full Text] [Related]

  • 5. Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents.
    Kowalczyk OS, Cubillo AI, Smith A, Barrett N, Giampietro V, Brammer M, Simmons A, Rubia K.
    Eur Neuropsychopharmacol; 2019 Oct 15; 29(10):1102-1116. PubMed ID: 31358436
    [Abstract] [Full Text] [Related]

  • 6. Methylphenidate normalizes frontocingulate underactivation during error processing in attention-deficit/hyperactivity disorder.
    Rubia K, Halari R, Mohammad AM, Taylor E, Brammer M.
    Biol Psychiatry; 2011 Aug 01; 70(3):255-62. PubMed ID: 21664605
    [Abstract] [Full Text] [Related]

  • 7. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study.
    Chou TL, Chia S, Shang CY, Gau SS.
    Eur Neuropsychopharmacol; 2015 Dec 01; 25(12):2300-10. PubMed ID: 26409297
    [Abstract] [Full Text] [Related]

  • 8. Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder.
    Bédard AC, Stein MA, Halperin JM, Krone B, Rajwan E, Newcorn JH.
    J Child Psychol Psychiatry; 2015 Jan 01; 56(1):40-8. PubMed ID: 24942409
    [Abstract] [Full Text] [Related]

  • 9. Single-dose effects of methylphenidate and atomoxetine on functional connectivity during an n-back task in boys with ADHD.
    Kowalczyk OS, Cubillo AI, Criaud M, Giampietro V, O'Daly OG, Mehta MA, Rubia K.
    Psychopharmacology (Berl); 2023 Oct 01; 240(10):2045-2060. PubMed ID: 37500785
    [Abstract] [Full Text] [Related]

  • 10. Prefrontal grey and white matter neurometabolite changes after atomoxetine and methylphenidate in children with attention deficit/hyperactivity disorder: a (1)H magnetic resonance spectroscopy study.
    Husarova V, Bittsansky M, Ondrejka I, Dobrota D.
    Psychiatry Res; 2014 Apr 30; 222(1-2):75-83. PubMed ID: 24679996
    [Abstract] [Full Text] [Related]

  • 11. Methylphenidate normalizes fronto-striatal underactivation during interference inhibition in medication-naïve boys with attention-deficit hyperactivity disorder.
    Rubia K, Halari R, Cubillo A, Smith AB, Mohammad AM, Brammer M, Taylor E.
    Neuropsychopharmacology; 2011 Jul 30; 36(8):1575-86. PubMed ID: 21451498
    [Abstract] [Full Text] [Related]

  • 12. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
    Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C, 31001074-ATT2001 Study Investigators.
    CNS Drugs; 2012 May 01; 26(5):421-34. PubMed ID: 22519922
    [Abstract] [Full Text] [Related]

  • 13. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M, Munda B, Svab V, Locatelli I.
    J Affect Disord; 2015 Jun 01; 178():149-59. PubMed ID: 25813457
    [Abstract] [Full Text] [Related]

  • 14. Effects of atomoxetine and methylphenidate on sleep in children with ADHD.
    Sangal RB, Owens J, Allen AJ, Sutton V, Schuh K, Kelsey D.
    Sleep; 2006 Dec 01; 29(12):1573-85. PubMed ID: 17252888
    [Abstract] [Full Text] [Related]

  • 15. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P.
    Curr Med Res Opin; 2014 Aug 01; 30(8):1673-85. PubMed ID: 24627974
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the inhibitory and excitatory effects of ADHD medications methylphenidate and atomoxetine on motor cortex.
    Gilbert DL, Ridel KR, Sallee FR, Zhang J, Lipps TD, Wassermann EM.
    Neuropsychopharmacology; 2006 Feb 01; 31(2):442-9. PubMed ID: 16034446
    [Abstract] [Full Text] [Related]

  • 17. Acute neuropharmacological effects of atomoxetine on inhibitory control in ADHD children: a fNIRS study.
    Nagashima M, Monden Y, Dan I, Dan H, Tsuzuki D, Mizutani T, Kyutoku Y, Gunji Y, Hirano D, Taniguchi T, Shimoizumi H, Momoi MY, Watanabe E, Yamagata T.
    Neuroimage Clin; 2014 Feb 01; 6():192-201. PubMed ID: 25379431
    [Abstract] [Full Text] [Related]

  • 18. Shared and Unique Effects of Long-Term Administration of Methylphenidate and Atomoxetine on Degree Centrality in Medication-Naïve Children With Attention-Deficit/Hyperactive Disorder.
    Fu Z, Yuan J, Pei X, Zhang K, Xu C, Hu N, Xie R, Zhao Y, Wang Y, Yang L, Cao Q.
    Int J Neuropsychopharmacol; 2022 Sep 28; 25(9):709-719. PubMed ID: 35524732
    [Abstract] [Full Text] [Related]

  • 19. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP, Keating GM.
    Paediatr Drugs; 2009 Sep 28; 11(3):203-26. PubMed ID: 19445548
    [Abstract] [Full Text] [Related]

  • 20. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, Lehmann M, Lehmkuhl G, Wehmeier PM.
    J Child Adolesc Psychopharmacol; 2011 Apr 28; 21(2):97-110. PubMed ID: 21488751
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.